LINC01118 and cancer: While LINC01119 did not enhance certain malignant traits of human cancer cells, such as resistance to suspension-induced cell death (anoikis; Supplementary Fig. 5b), it did promote significant increases in cell proliferation (Fig. 3a) and promoted cell cycle progression in SUM159 cells (Fig. 3b), enhanced the clonogenic growth of both SUM159 and MDA-MB-231 cells in 2D (Fig. 3c), as well as triggered 2-9-fold increase in the anchorage-independent growth of these cells in soft-agar assays (Fig. 3d).